Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
AbbVie (NYSE: ABBV) today announced the New England Journal of Medicine (NEJM) published results from the pivotal Phase 3 clinical trials – U-EXCEL,...
- Five-year results from SELECT-COMPARE evaluating the efficacy and safety of RINVOQ® (upadacitinib) and HUMIRA® (adalimumab), both in combination...
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLYTM (epcoritamab-bysp), as the first and only ...
– The co-primary endpoints of endoscopic response (visible reduction of intestinal lining damage) and clinical remission were achieved by...
Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of SKINVIVE™ by JUVÉDERM® to improve skin smoothness of...
AbbVie (NYSE: ABBV) today announced it will present 29 abstracts during the 2023 Digestive Disease Week (DDW) Annual Meeting, May 6-9, 2023, being...
AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Tuesday, May 9, 2023. Robert A. Michael, vice...
Reports First-Quarter Diluted EPS of $0.13 on a GAAP Basis, a Decrease of 94.8 Percent; Adjusted Diluted EPS of $2.46, a Decrease of 22.2 Percent;...
The Phase 3 ELEVATE study demonstrated atogepant is effective and well-tolerated for the preventive treatment of episodic migraine in people who...
Allergan Aesthetics, an AbbVie company, supports women plastic surgeons and the development of current and future leaders in science, healthcare, and ...
QULIPTA® now the first and only oral CGRP receptor antagonist approved to prevent migraine across frequencies, including episodic and chronic...
– Seventh approved indication for RINVOQ in the European Union (EU) and the first and only oral Janus Kinase (JAK) inhibitor approved to treat adult...
AbbVie today announced that the AbbVie Cystic Fibrosis (CF) Scholarship, a program that is making a difference in the lives of young adults with CF...
Resultados do estudo clínico de fase 2 denominado M19-130 ("SLEek") com upadacitinibe em monoterapia, ou como uma terapia combinada (ABBV-599,) para...
AbbVie (NYSE: ABBV) will announce its first-quarter 2023 financial results on Thursday, April 27, 2023, before the market opens. AbbVie will host a...
Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and the parent company of CoolSculpting® Elite, announces the first ever CoolMonth, taking place...
Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, will be showcasing its customer-centric 'Discover Your 360°' approach to aesthetics at the 21st...
Results of the M19-130 (SLEek) Phase 2 trial of upadacitinib given alone or as a combination therapy (ABBV-599) met the primary endpoint of systemic...
A significantly higher proportion of patients with moderately to severely active ulcerative colitis treated with risankizumab achieved the primary...
AbbVie (NYSE: ABBV) today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug...
Treatment with SKYRIZI (risankizumab) demonstrated short- and long-term efficacy of psoriasis signs and symptoms (sPGA 0/1) at week 16 and week 52 in ...
AbbVie (NYSE: ABBV) today announced the launch of a new documentary film, "Under My Skin: Untold Stories of Life with Eczema," which debuted at South ...
AbbVie (NYSE: ABBV) today announced it will present more than 20 abstracts, including one late-breaking presentation during the 2023 American Academy ...
A AbbVie (NYSE: ABBV) e a Capsida Biotherapeutics Inc. ("Capsida") anunciaram (23/03/23) a ampliação de uma colaboração estratégica para...
In honor of International Women's Day, Allergan Aesthetics, an AbbVie company (NYSE: ABBV) today announced that BOTOX® Cosmetic is partnering with...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.